Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Inactivated EV71 Vaccine in Healthy Infants
NCT01507857Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jan 2012
- Primary completion
- Mar 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in HIV-associated central nervous system involvement (HAND) comparing EV71 Vaccine with Placebo (2 arms). Primary endpoint: Incidence rate of Hand, Foot and Mouth disease caused by EV71 at 1 year. Started Jan 2012; status: completed.
02
Drugs
enterovirus 71 vaccine (vero cell), inactivated
03
Conditions
HIV-associated central nervous system involvement (HAND)
Beyond the preview
Go deeper on NCT01507857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01507857.